Top

European Child & Adolescent Psychiatry

Published in:

01-04-2009 | ORIGINAL CONTRIBUTION

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder

A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents

Authors: Pär Svanborg, Gunilla Thernlund, Per A. Gustafsson, Bruno Hägglöf, Lynne Poole, Björn Kadesjö

Published in: European Child & Adolescent Psychiatry | Issue 4/2009

Abstract

Objective

The primary objective of this study was to assess the impact of atomoxetine in combination with psychoeducation, compared with placebo and psychoeducation, on health-related quality of life (HRQL) in Swedish stimulant-naïve pediatric patients with attention deficit/hyperactivity disorder (ADHD). HRQL results will be presented elsewhere. Here, psychoeducation as well as efficacy and safety of the treatment are described.

Patients and methods

A total of 99 pediatric ADHD patients were randomized to a 10-week double-blind treatment with atomoxetine (49 patients) or placebo (50 patients). Parents of all patients received four sessions of psychoeducation. Atomoxetine was dosed up to approximately 1.2 mg/kg day (≤70 kg) or 80 mg/day (>70 kg). Improvement of ADHD symptoms was evaluated using the ADHD rating scale (ADHD-RS) and clinical global impression (CGI) rating scales. Safety was assessed based on adverse events (AEs).

Results

The study population was predominantly male (80.8%) and diagnosed with the combined ADHD subtype (77.8%). The least square mean (lsmean) change from baseline to endpoint in total ADHD-RS score was −19.0 for atomoxetine patients and −6.3 for placebo patients, resulting in an effect size (ES) of 1.3 at endpoint. Treatment response (reduction in ADHD-RS score of ≥25 or ≥40%) was achieved in 71.4 or 63.3% of atomoxetine patients and 28.6 or 14.3% of placebo patients. The lsmean change from baseline to endpoint in CGI-Severity was −1.8 in the atomoxetine group compared with −0.3 in the placebo group. The difference between treatments in CGI-Improvement at endpoint was −1.4 in favor of atomoxetine. No serious AEs occurred. The safety profile of atomoxetine was in line with the current label.

Conclusions

Atomoxetine combined with psychoeducation was superior to placebo and psychoeducation in ADHD core symptoms improvement. The large ES might be a result of including stimulant-naïve patients only, but also may indicate a positive interaction between atomoxetine treatment and psychoeducation, possibly by increased compliance.

American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR, Washington

Remschmidt H, Global ADHD Working Group (2005) Global consensus on ADHD/HKD. Eur Child Adolesc Psychiatry 14(3):127–137PubMedCrossRef

Biederman J, Faraone SV, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J (1996) A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437–446PubMed

Gillberg C, Kadesjo B (2003) Why bother about clumsiness? The implications of having developmental coordination disorder (DCD). Neural Plast 10(1–2):59–68PubMedCrossRef

Goldman LS, Genel M, Bezman RJ, Stanetz PJ (1998) Diagnosis and treatment of attention-deficit/hyperactivity disorders in children and adolescents. JAMA 279:1100–1107PubMedCrossRef

Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, Snyder LE, Faraone SV (2006) Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 36(2): 167–179PubMedCrossRef

Biederman J, Faraone SV (2005) Attention-deficit/hyperactivity disorder. Lancet 366:237–248PubMedCrossRef

Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I (2005) Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 116:364–369CrossRef

Bernet W, Dulcan MK, Greenhill LL, Pliszka SR (2004) AACAP-endorsed managing: attention-deficit/hyperactivity disorder. Guidelines (pocketcard) version 2.0 American academy of child and adolescent psychiatry. International guidelines center. Available at: http://www.myguidelinescenter.com

10.

UK Strattera SPC (2007)

11.

Kelsey D, Sumner C, Casat C, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ (2004) Once-daily atomoxetine treatment for children with attention-deficit hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114(1):e1–e8PubMedCrossRef

12.

Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wenicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896–1901PubMedCrossRef

13.

Michelson D, De Faires, Wenicke J, Kelsey DK, Kendrick KL, Sallee FR, Spencer T, Atomoxetine ADHD Study Group (2001) Atomoxetine in the treatment of children and adolescents with ADHD: a randomized, placebo-controlled dose-response study. Pediatrics 108:e83PubMedCrossRef

14.

Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ (2002) Results from 2 proof-of-concept, placebo- controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140–1147PubMed

15.

Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, Tamura R, Kelsey D, Stevens L, Allen AJ (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 44(7):647–655PubMedCrossRef

16.

Mosholder AD (2006) Psychiatric adverse advents in attention-deficit/hyperactivity disorder (ADHD) clinical trials. Food and Drug Administration, Pediatric Advisory Committee, 22 March, 2006. Available at: http://www.fda.gov/ohrms/dockets/AC/06/slides/2006–4210s_14_Mosholder_PsychiatricAdverse Events_files/frame.htm

17.

Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF (2004) The parent report form of the CHIP-child edition: reliability and validity. Med Care 42(3):210–220PubMedCrossRef

18.

RileyAW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G (2006) Validity of the health-related quality of life assessment in the ADORE study: parent report form of the CHIP-child edition. Eur Child Adolesc Psych 15(Suppl 1):1/63–1/71. doi:10.1007/ s00787–006-1009-6

19.

Weiss MD, Virani A, Wasdell M, Faulkner M, Rea K, Freeman RD, Weiss G, Jokhani V (2006) Atomoxetine in clinical practice. Future Neurol 1(3): 249–258CrossRef

20.

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36(7):980–989PubMedCrossRef

21.

DuPaul GJ, Power TJ, Anastopoloulos AD, Reid R (1998) ADHD rating scale-IV checklist, norms and clinical interpretation. The Guilford Press, New York

22.

Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001) Validation of the ADHD rating scale as a clinician administered and scored instrument. J Atten Disord 5:39–47CrossRef

23.

Guy W (1976) ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health (NIMH), Psychopharmacology Research Branch (revised 1976)

24.

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen H-C, Sonuga-Barke EJS, Taylor E (2006) Long-acting medication for the hyperkinetic disorders. A systematic review and European treatment guidelines. Eur Child Adolesc Psychiatry. doi:10.1007/s00787-006-0549-0

25.

Sutton VK, Milton DR, Ruff DD, Allen AJ (2004) Atomoxetine’s efficacy over time in children and adolescents with attention-deficit/hyperactivity disorder. In: Poster presented at AACAP, Washington, 19–24 October, 2004

26.

Newcorn JH, Kratochvil CJ, Allen AJ, Milton DR, Moore R, Michelson D (2005) Atomoxetine and OROS methylphenidate for the treatment of ADHD: acute results and methodological issues. In: Poster presented at NCDEU

27.

van der Oord S, Prins PJM, Oosterlaan J, Emmelkamp PMG (2007) Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD? Eur Child Adolesc Psychiatry 16:48–57PubMedCrossRef

28.

MTA Cooperative Group (1999) Moderators and mediators of treatment reponse for children with attention-deficit/hyperactivity disorder. Arch Gen Psych 56:1088–1096CrossRef

29.

MTA Cooperative Group (1999) A 14 month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psych 56:1073–1086CrossRef

30.

McLeary L, Ridley T (1999) Parenting adolescents with ADHD: evaluation of a psychoeducation group. Parent Education Councelling 38:3–10CrossRef

31.

Monastra VJ (2005) Overcoming the barriers to effective treatment for attention-deficit/hyperactivity disorder: a neuron-educational approach. Int J Psychophysiol 58:71–80PubMedCrossRef

32.

Jensen PS, Martin D, Cantwell DP (1997) Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Child Adolesc Psychiatry 36:1065–1079CrossRef

33.

August GJ, Realmuto GM, MacDonald AW 3rd, Nurent SM, Crosby R (1996) Prevalence of ADHD and comorbid disorder among elementary children screened for disruptive behavior. J Abnorm Child Psychol 24:571–595PubMedCrossRef

34.

Buitelaar JK, Barton J, Danckaerts M, Friedrichs E, Gillberg C, Hazell PL, Hellemans H, Johnson M, Kalverdijk LJ, Masi G, Michelson D, Revol O, Sebastian JS, Zhang S, Zuddas A (2006) A comparison of North American versus non-North American ADHD study populations. Eur Child Adolesc Psychiatry 15:177–181PubMedCrossRef

35.

Greene RW, Biederman J, Zerwas S, Monuteaux MC, Goring JC, Faraone SV (2002) Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychol 159:1214–1224CrossRef

36.

Kuhne M, Schachar R, Tannock R (1997) Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivitiy disorder. J Am Acad Child Adolesc Psychiatry 36:1715–1725PubMedCrossRef

37.

Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D (2005) Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44: 3240–3248CrossRef

38.

Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C (2007) Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46(9):1119–1127PubMedCrossRef

Title: Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder
A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents
Authors: Pär Svanborg
Gunilla Thernlund
Per A. Gustafsson
Bruno Hägglöf
Lynne Poole
Björn Kadesjö
Publication date: 01-04-2009
Publisher: Steinkopff-Verlag
Published in: European Child & Adolescent Psychiatry / Issue 4/2009
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-008-0725-5

At a glance: The STEP trials

Springer Medicine

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder

A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents

Abstract

Objective

Patients and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2009

Prevalence and correlates of mental disorders among adolescents in Italy: the PrISMA study

Appleton, Peter (ed.), “Children’s anxiety. A contextual approach”

Fathers’ parenting, adverse life events, and adolescents’ emotional and eating disorder symptoms: the role of emotion regulation

Comparing different modes of delivery

Moderate clinical improvement with maintenance ECT in a 17-year-old boy with intractable catatonic schizophrenia

G6PD deficiency in autism